熱門資訊> 正文
第32季度生物GAAP每股收益为-0.78美元
2025-08-06 19:45
- Q32 Bio press release (NASDAQ:QTTB): Q2 GAAP EPS of -$0.78.
- Cash and cash equivalents were $54.8 million as of June 30, 2025. Q32 Bio believes its cash and cash equivalents are sufficient to fund operations into 2027, through the SIGNAL-AA OLE and topline results of the SIGNAL-AA Part B trial evaluating bempikibart in patients with AA expected in the first half of 2026.
More on Q32 Bio
- Seeking Alpha’s Quant Rating on Q32 Bio
- Historical earnings data for Q32 Bio
- Financial information for Q32 Bio
風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。